Table 1 Baseline characteristics
Baseline characteristics | Aspergillus fumigatus | No persistent Aspergillus fumigatus | p-value |
|---|---|---|---|
n (%) | n (%) | ||
Total | 64 (15) | 373 (85) | |
Demographics and CF characteristics | |||
Age, years (mean ± SD) | 21.5 ± 12.8 | 23.9 ± 13.4 | 0.18 |
Female sex | 30 (47) | 178 (48) | 0.90 |
Homozygous DeltaF508 | 35 (55) | 161 (43) | 0.09 |
CF-related diabetes | 15 (23) | 62 (17) | 0.19 |
Pancreatic insufficiency | 61 (95) | 320 (86) | 0.035 |
Microorganisms | |||
Chronic PsA colonization | 17 (28) | 155 (42) | 0.040 |
Treatments | |||
Inhaled antibiotics | 33 (54) | 118 (33) | 0.001 |
Inhaled corticosteroids | 15 (23) | 122 (33) | 0.12 |
Macrolides | 12 (19) | 136 (37) | 0.005 |
Inhaled rhDNase | 22 (34) | 107 (29) | 0.38 |
Lung function and other clinical parameters | |||
ppFEV1 (mean ± SD) | 81.2 ± 21.9 | 79.1 ± 22.7 | 0.50 |
ppFVC (mean ± SD) | 94.7 ± 16.1 | 93.5 ± 17.1 | 0.59 |
Number of IV-antibiotics (median (IQR)) | 1 (0–2) | 1 (0–3) | 0.66 |
Hospitalization days (median (IQR)) | 0 (0–2) | 0 (0–0) | 0.081 |
Total IgE (median (IQR))a | 40.0 (10.5–77.0) | 41.5 (16.5–120.0) | 0.39 |
Eosinophils (median (IQR))b | 0.3 (0.1–0.4) | 0.2 (0.1–0.3) | 0.086 |